Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/Hisun to collaborate in China

Pfizer has announced it is to work with Zhejiang Hisun Pharmaceuticals to develop and market generic drugs in China

Pfizer has announced it is to work with Zhejiang Hisun Pharmaceuticals to develop and market generic drugs in China.

The companies have signed a memorandum of understanding on their intention to establish a joint venture with a focus on research, development and commercialisation of off-patent medicines to help build the presence of both firms in the country.

Both parties can contribute existing products and assets to provide a platform for the collaboration.

The move follows a similar agreement Pfizer signed with Chinese company Shanghai Pharmaceuticals, which included distribution and commercialisation, research and development activities, manufacturing and equity investment opportunities.

According to Pfizer, branded generics account for 60 per cent of the domestic market in China, with the country expected to become the world's second-largest pharmaceutical market by 2015.

Hua Bai, CEO and president of Hisun Pharmaceuticals, stated that such deals were the way forward for the company. He said: "Collaborating with the world's leading pharmaceutical companies to form potential joint ventures is a strategy being adopted by Hisun."

6th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics